格隆汇8月26日丨昭衍新药(603127.SH)公布，2025年1月1日至本公告披露日，及公司下属子公司累计收 到各类政府补助共计人民币2,885.28万元（数据未经审计）。其中，与收益相关的政府补助1,448.08万 元，占公司最近一个会计年度经审计的归属于上市公司股东净利润的比例为19.55%；与资产相关的政 府补助1,437.20万元，占公司最近一个会计年度经审计的归属于上市公司股东净资产的比例为0.18%。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) is establishing a seed fund in collaboration with investment management firms to focus on strategic emerging industries, particularly in biomedicine and high-end medical devices [1] Group 1 - The company plans to sign a partnership agreement with Yifeng Capital and Yifeng Mingyuan Technology to set up the Shenzhen Yifeng Guangming Science City Seed Fund [1] - The fund will target investments in industries supported by the Shenzhen government, emphasizing biomedicine and high-end medical devices [1] - The company or its designated subsidiary will contribute no more than 10 million RMB as a limited partner in the fund [1]

Core Viewpoint - The company is establishing a seed fund in collaboration with professional investment institutions to invest in strategic emerging industries, particularly in the biomedicine and high-end medical equipment sectors [1][2]. Group 1: Fund Establishment - The company, along with its designated subsidiaries, plans to sign a partnership agreement to establish the Shenzhen Yifeng Guangming Science City Seed Fund, with a maximum investment of 10 million RMB [1]. - The fund aims to support and develop strategic emerging industries and other key industries promoted by the Shenzhen government [1]. Group 2: Strategic Alignment - This investment aligns with the company's long-term development strategy and will leverage the resources and expertise of its partners to broaden investment channels [2]. - The collaboration is expected to provide momentum and assurance for the company's sustainable high-quality development [2]. Group 3: Risk Management - The company will benefit from the management experience and risk control systems of the fund managers, which will help mitigate investment risks and ensure project quality [2]. - The investment is not expected to have a significant adverse impact on the company's operations or performance, and it does not involve management changes or create competition [2].

Core Insights - The company reported a revenue of approximately 669 million, representing a year-on-year decrease of 21.3% [1] - Gross profit was about 105 million, down 50.3% year-on-year [1] - Net profit was 60.93 million, marking a turnaround from a loss to profit [1] - Earnings per share stood at 0.08 [1] Revenue and Profit Analysis - The decline in revenue is primarily attributed to intensified competition leading to a decrease in project unit prices [1] - The increase in net profit is mainly due to changes in the fair value of biological assets [1] - The company recognized a gain of 95 million from the fair value changes of biological assets during the period [1] Biological Assets Performance - For the six months ending June 30, 2025, the gains from biological assets were driven by natural growth [1] - In contrast, for the six months ending June 30, 2024, the company reported a loss of 254.4 million, primarily due to a decrease in the unit fair value of biological assets, consistent with the decline in market prices of experimental models [1]

Core Viewpoint - Zhaoyan New Drug (06127) announced that it has received a total of RMB 28.85 million in various government subsidies from January 1, 2025, to the date of this announcement, with the data being unaudited [1] Summary by Category - Government Subsidies Received - The company received a total of RMB 28.85 million in government subsidies [1] - Among these, subsidies related to income amounted to RMB 14.48 million, accounting for 19.55% of the company's audited net profit attributable to equity shareholders for the most recent fiscal year [1] - Asset-related government subsidies totaled RMB 14.37 million, representing 0.18% of the company's audited net assets attributable to equity shareholders for the most recent fiscal year [1]

Group 1 - The company announced a partnership with Yifeng Capital and related parties to establish a seed fund focused on strategic emerging industries, particularly in biomedicine and high-end medical devices [1][2] - The company plans to invest up to 10 million RMB in the fund, which aligns with its long-term development strategy and aims to leverage the expertise of professional investment institutions [1][2] - The investment is expected to enhance the company's investment channels and support sustainable high-quality development without significantly impacting its operations or financial performance [2] Group 2 - The partnership is designed to utilize the management experience and risk control systems of the fund managers, which will help mitigate investment risks and ensure project quality [2] - The investment will not lead to management changes, personnel adjustments, land leasing issues, or create any competition within the industry [2]

昭衍新药（603127）(06127)发布公告，集团自2025年1月1日至本公告披露日累计收到各类政府补助共 计人民币2885.28万元(数据未经审计)。 其中，与收益相关的政府补助1448.08万元，占公司最近一个会计年度经审计的归属于公司权益股东净 利润的比例为19.55%;与资产相关的政府补助1437.2万元，占公司最近一个会计年度经审计的归属于公 司权益股东净资产的比例为0.18%。 ...

昭衍新药（603127）(06127)公布2025年中期业绩，收益约6.69亿元，同比减少21.3%;毛利约1.05亿元， 同比减少50.3%;净利6093.2万元，同比扭亏为盈;每股盈利0.08元。 公告称，收益减少主要是由于竞争加剧导致项目单位价格下滑所驱动。净利润增加主要是由于生物资产 公平值变动。期内确认生物资产公平值变动产生的收益9500万元，截至2024年6月30日止六个月则为亏 损2.544亿元。截至2025年6月30日止六个月产生的收益主要是由于生物资产自然生长带来的，而截至 2024年6月30日止六个月的亏损主要是由于生物资产的单位公平值减少，与实验模型的市价下降相符。 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-031 北京昭衍新药研究中心股份有限公司 本次会议经与会董事认真审议，以举手表决方式作出了如下决议： 1.审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 表决结果：董事会以 9 票赞成、0 票反对、0 票弃权的表决结果通过该议案。 上述议案已经公司董事会审计委员会审议通过，同意相关内容并同意提交公 司董事会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）及公司 指定信息披露媒体《上海证券报》披露的《北京昭衍新药研究中心股份有限公司 2025 年半年度报告》。 2.审议通过《关于公司与专业投资机构合作参与投资设立基金的议案》 公司董事会同意公司或其指定子公司与专业投资机构合作参与投资设立基 金，公司或其指定子公司作为有限合伙人认缴出资不超过 1,000 万元人民币。 第四届董事会第十五次会议决议公告 表决结果：董事会以 9 票赞成、0 票反对、0 票弃权的表决结果通过该议案。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 证券代码：603127 证券简称：昭衍新药 公告编号：2025-031 北京昭衍新药研究中心股份有限公司 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年8月26日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 ...